Taysha Gene Therapies Inc. (TSHA) is ‘Market Perform’ on Rett Syndrome Therapy: JMP Securities

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy now. On September 12, analysts at JMP Securities reiterated a ‘Market Perform’ rating on the stock and a $6 price target.

The positive stance follows the stock’s impressive 56% year-to-date gain. It also follows solid second-quarter results, whereby revenue totaled $1.98 million, exceeding analysts’ estimates of $1.82 million.

The stock’s sentiments have also received a significant boost from the development of TSHA-102 for Rett Syndrome. The gene therapy edge stems from its ability to provide consistent distribution across the brain while leveraging the AAV9 vector.

The treatment has already been administered to 12 patients, with no serious adverse events reported. The company plans to begin patient enrollment in the fourth quarter, meeting key FDA requirements.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company dedicated to advancing and commercializing gene therapies for serious monogenic conditions affecting the central nervous system. The company utilizes adeno-associated virus vectors to treat disorders stemming from single-gene mutations.

READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.